Navigation Links
A new drug treatment to close the window on colon cancer
Date:7/21/2010

Cancer surgery wreaks havoc on a body's immune system and stress hormones exacerbate the problem. As a result, about half of those who undergo surgery for tumor removal experience a recurrence of cancer in the same region or other parts of the body.

A new clinical approach being developed and tested by Tel Aviv University researchers may be the key to making cancer operations more successful. Prof. Shamgar Ben-Eliyahu, head of Tel Aviv University's Department of Psychology, has opened on a new frontier in cancer research: he is recruiting colon cancer patients for a new clinical study which will test a cocktail of drugs to prevent the negative effects of stress responses to surgery. If successful, it will help the immune system maintain its vigor and prevent the occurrence of new tumors.

Prof. Ben-Eliyahu described his method in a recent issue of the Journal of Immunology.

A more competent immune system

Prof. Ben-Eliyahu and other research teams have confirmed that a competent immune system is critical before, during and after surgery for tumor removal. However, stress responses of the body during this period jeopardize immune competence and facilitate tumor metastasis.

Combining two widely-known medications that affect immune and stress responses, Prof. Ben-Eliyahu has developed a formula he hopes will keep an immune system strong and prevent the recurrence of cancer. Already tested in animal models, the compounds will be employed in a clinical trial in Israel, for which Prof. Ben-Eliyahu's team is currently recruiting patients and funds. They hope to have 800 colon cancer patients participate in the trial, due to begin shortly.

Increasing survival 300%

According to Prof. Ben-Eliyahu, the main stress hormones that appear to negatively impact immune system functioning are released before and during surgery. He says that existing generic drugs could block the influence of th
'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

0

GOOD

Page: 1 2

Related medicine news :

1. Improved treatment access requires end to portrayal of drug abusers as already dead
2. Writing checks that bounce: World continues to backtrack on HIV treatment
3. HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study
4. New discovery brings hope to treatment of incurable blood cancer
5. Shoulder arthritis? What patients need to know before treatment
6. Rare Blood Vessel Disease Could Have New Treatment Option
7. NIH awards Scripps Florida scientists $2.3 Million to develop drug addiction treatments
8. New treatment for crippling diabetic Charcot foot
9. Arsenic shows promise as cancer treatment, Stanford study finds
10. Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic
11. Discovery Opens Door for New Options in Prevention and Treatment of Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new drug treatment to close the window on colon cancer
(Date:5/23/2013)... 23, 2013 Amirsys, Inc. will ... learning environment for all resident levels this July. ... transforms the learning experience from case-based learning to ... , “Until RADPrimer 3.0, RADPrimer heavily emphasized a ... Dr. B.J. Manaster, Professor of Radiology at the ...
(Date:5/23/2013)... it when a woman harried by hot flashes says ... study published online in Menopause , the journal ... with objective tests that what these women say about ... studies showed that hot flashes were related to memory ... though there was a relationship between hot flashes and ...
(Date:5/23/2013)... dragged to its destruction inside a cell, a ... that thwart the development of tumor-suppressing microRNAs (miRNAs) ... online publication at Nature . , Under ... the epidermal growth factor receptor (EGFR) gums up ... by scientists at The University of Texas MD ...
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... products manufactured by C.R. Bard, Inc., continue to move ... District Court, Southern District of West Virginia, Bernstein Liebhard ... 17th, the Court denied a request by C.R. Bard ... claimed would reveal trade secrets and other confidential, proprietary ...
(Date:5/23/2013)... New York, NY (PRWEB) May 23, 2013 ... http://bit.ly/Z4m6UI , Canadian tech start-ups are increasingly seeing ... deals with larger US-based companies, according to ... business development engine. , The company has compiled ... entitled Borderless Investments. The findings of the research have ...
Breaking Medicine News(10 mins):Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4
... The National Commander of the Disabled American Veterans begins ... support for budget reform legislation to ensure sufficient, timely ... is urging them to reject a contentious proposal that ... conditions from the government,s side of the ledger to ...
... cranberriesand not the acidity of cranberry juice, as previously ... line the urinary tract, as documented in a report ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ... www.liebertpub.com/jmf , Urinary tract infections (UTIs) burden ...
... March 9 Quest Diagnostics Incorporated (NYSE: ... information and services, announced that it is scheduled to ... on Tuesday, March 10, 2009. The Quest Diagnostics ... Time.During the conference, the company will reaffirm its 2009 ...
... Sport Beans and Nike Motivate College Students to Complete ... SpringNEW YORK, March 9 American Collegiate Intramural Sports ... corporate sponsors are joining together to launch ACIS Fitness ... college marketing platform is aimed at motivating the 2.7 ...
... Japanese scientists will arrive at the University of Houston ... that promises to deliver more comprehensive and accurate insights ... of current technologies. , In April, Mikio Kubota of ... join the research team at UH,s Biomedical Imaging Lab. ...
... President Obama signed an executive order ... stem cell research, overturning limits on federal funding for ... President & CEO of Americans United for Life responded, ... past. Millions of dollars have been spent on ...
Cached Medicine News:Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:New research reveals how cranberry products prevent urinary tract infections 2Health News:Quest Diagnostics to Speak at Barclays Capital Global Healthcare Conference 2Health News:ACIS Fitness Challenges Launch Across 200 Colleges Nationwide 2Health News:UH research team developing new noninvasive brain-mapping technology 2Health News:UH research team developing new noninvasive brain-mapping technology 3Health News:UH research team developing new noninvasive brain-mapping technology 4Health News:Americans United for Life: Obama Administration Stem Cell Policy an Anti-Life Waste of Tax Dollars 2
(Date:5/23/2013)... YORK , May 23, 2013  Intercept Pharmaceuticals, ... stage biopharmaceutical company focused on the development and commercialization ... diseases, such as primary biliary cirrhosis, today announced that ... Chief Executive Officer, will present at the Deutsche Bank ... Boston on Wednesday, May 29, 2013 at ...
(Date:5/23/2013)...  MedVantx, Inc., the company that has pioneered a ... the Company has completed a major expansion of its ... and the upgrade of its systems to offer a ... specialty home delivery pharmacy in Sioux Falls, ... physicians, health systems and payors novel distribution services, as ...
(Date:5/23/2013)... PARIS , May 23, 2013 ... (NYSE MKT: NSPR), the leader in embolic protection ... MASTER (MGuard for Acute ST Elevation Reperfusion) trial ... outperformed bare metal and drug eluting stents in ... (STEMI) patients.  Results from the trial were presented ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
... design of Sleepscan VISION ensures flexibility in ... opportunities. Sleepscan VISION utilizes the powerful Netlink ... through a standard Ethernet connection. Only computer ... allowing the Sleepscan VISION to take advantage ...
... Digital EEG ,The company that introduced ... the latest addition to the Ceegraph ... innovative system incorporates the latest developments ... management to offer you unprecedented portability, ...
... MOBEE headboxes are ... XLTEK's line of portable ... with a robust new ... latest software, XLTEK's standard ...
... SL 130 Slit Lamp is an all-in-one instrument ... structured design also allows the SL 130 to ... achieved by the possibility of operating the slit ... left or right hand. The instrument configuration allows ...
Medicine Products: